Does Prenatal Methamphetamine Exposure Induce Sensitization to Drugs in Adulthood?

E. MACÚCHOVÁ¹, R. ŠLAMBEROVÁ¹

¹Department of Normal, Pathological and Clinical Physiology, Third Faculty of Medicine, Charles University, Prague, Czech Republic

Received April 10, 2017
Accepted October 25, 2017

Summary
Behavioral sensitization is defined as augmented psychomotor activity, which can be observed after drug re-administration following withdrawal of repeated drug exposure. It has been shown that abuse of one drug can lead to increased sensitivity to certain other drugs. This effect of developed general drug sensitivity is called cross-sensitization and has been reported between drugs with similar as well as different mechanisms of action. There is growing evidence that exposure to drugs in utero not only causes birth defects and delays in infant development, but also impairs the neural reward pathways, in the brains of developing offspring, in such a way that it can increase the tendency for drug addiction later in life. This review summarizes the results of preclinical studies that focused on testing behavioral cross-sensitization, after prenatal methamphetamine exposure, to drugs administered in adulthood, with both similar and different mechanisms of action. Traditionally, behavioral sensitization has been examined using the Open field or the Laboras Test to record locomotor activity, and the Conditioned Place Preference and Self-administration test to examine drug-seeking behavior. However, it seems that prenatal drug exposure can sensitize animals not only to the locomotor-stimulating and conditioning effects of drugs, but may also be responsible for modified responses to various drug effects.

Key words
Methamphetamine • Drug abuse • Sensitization • Prenatal drug exposure

Introduction

Drug abuse during pregnancy is a serious problem in many countries around the world. Many of the abused drugs can easily cross the placental barrier, and thus women, who take drugs during pregnancy, expose not only themselves but their developing fetus to the harmful effects of the drugs they take. The consequences of prenatal drug exposure are long-lasting and may even continue into adulthood. The question remains whether exposure to a drug of abuse in utero can affect the brain of a developing animal to the point that it leads to a greater predisposition towards drug abuse in adulthood. Several preclinical studies have observed the phenomenon of sensitization, as a progressive and enduring response produced by repeated intermittent prenatal drug administration (Malanga and Kosofsky 2003, Robinson and Berridge 1993, Suzuki et al. 2004).

Behavioral sensitization and cross-sensitization

In the context of the study of drug addiction, two important terms are defined. The first is tolerance, which refers to the decreased effectiveness of a drug with repeated administration, stated another way; it takes a higher dose of the drug to achieve the same level of response achieved initially. The second term, behavioral or psychomotor sensitization, is defined as a progressive
and enduring response produced by repeated intermittent drug administration with the same or lower dose (Suzuki et al. 2004). Behavioral sensitization is also referred to as reverse tolerance, behavioral augmentation, or facilitation (Robinson and Becker 1986). It was found that once enhanced drug sensitivity develops, it can persist for extended periods of time (Robinson and Becker 1986). The phenomenon of behavioral sensitization on the effects of various drugs has been observed in several preclinical studies – cocaine (COC) (Estelles et al. 2006), methamphetamine (MA) (Kučerová et al. 2010, Šlamberová et al. 2012, Ślamberová et al. 2011, Ślamberová et al. 2011), and morphine (Valjent et al. 2010).

A growing number of studies have shown that abuse of one drug can lead to increased sensitivity to another drug. Developed general drug sensitivity is called cross-sensitization (Shuster et al. 1977) and has been reported between drugs of similar mechanisms of action such as amphetamine (AMP) and COC (Bonate et al. 1997, Horger et al. 1992, Shuster et al. 1977) and between methylphenidate and AMP (Valvassori et al. 2007). Repeated AMP pre-treatment has been shown to sensitized animals to the locomotor activating effect of COC (Bonate et al. 1997, Shuster et al. 1977). In another study, pre-treatment with AMP enhanced COC self-administration (Ferrario and Robinson 2007). Additionally, cross-sensitization has been demonstrated between drugs with different mechanisms of action, e.g. between opioids and COC (He and Grasing 2004, Leri et al. 2003), and between cannabinoids and opioids (Fattore et al. 2005, Vela et al. 1998).

**The neural basis of behavioral sensitization**

Robinson and Berridge (1993) found that with repeated intermittent drug administration, brain regions involved in reward systems become hypersensitive to the specific drug, which results in a pathological drug craving. Despite numerous studies investigating sensitization as a complex process arising from different cellular changes over several brain regions, the neural basis of behavioral sensitization has not been thoroughly characterized. The development of behavioral sensitization after repeated intermittent administration of a psychostimulant is specifically based on changes in the dopaminergic system, i.e. nigrostriatal, mesolimbic, and mesocortical (Robinson and Becker 1986). According to the neural hypothesis, two phases of behavioral sensitization can be defined, (1) the initiation of behavioral sensitization occurs in the ventral tegmental area (VTA) and is defined by a transient sequence of cellular and molecular changes caused by drug administration, and (2) the neuronal events associated with expression of behavioral sensitization are distributed among the interconnected nuclei of motivation circuits and are defined as enduring neural alterations from the initiation process (Kalivas and Stewart 1991, Robinson and Becker 1986).

While an increase in extracellular dopamine (DA) (at the terminals on the nucleus accumbens (NAc)), induced by repeated injections of AMP, can be responsible for behavioral sensitization, increased DA levels in the cell body regions of the VTA have also been found to induce behavioral sensitization (Kalivas and Stewart 1991). Similar to animal models, repeated intermittent administration of AMP has been reported to cause sensitization of DA release in humans, which was still present after one year (Boileau et al. 2006). Although the essential role of dopaminergic receptor type 1, in behavioral sensitization, has been established in previously published studies using dopaminergic receptor type 1 antagonists, the involvement of dopaminergic receptors type 2 in this process is less clear (Ujike et al. 1989, Vezina and Stewart 1989). Additionally, not only DA but also other neurotransmitters have been shown to be necessary for the expression and induction of behavioral sensitization after psychostimulant treatment (Kalivas and Alesdatter 1993, Wolf 1998). Specifically, increased glutamate transmission in the NAc, striatum, and VTA was reported after repeated intracranial AMP administration (Wolf 1998, Xue et al. 1996). Moreover, after pre-treatment with the non-competitive N-Methyl-D-aspartic acid (NMDA) antagonist, MK-801, induction of behavioral sensitization was inhibited, indicating that NMDA and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors were involved (Stewart and Druhan 1993, Wolf and Jeziorski 1993). It is believed that these receptors are involved in long-term potentiation, which is a key process associated with learning and memory consolidation in the hippocampus (Pu et al. 2002, Ślamberová et al. 2014). Consequently, similar molecular and cellular mechanisms utilized by the brain to form normal memories as well as addiction-related memories could play a key role in the response to drugs later in life (Ślamberová et al. 2014, Thomas and Malenka 2003).

Nestler (2005) suggested that at least three
systems play a key role in the development of sensitization. First, as previously mentioned, chronic exposure to any of several commonly abused drugs impairs the VTA-NAc pathway; second, chronic exposure to drugs reduces basal activity in the frontal cortical regions (glutamate projections to the NAC and VTA), which can decrease self-control and increase impulsivity; and third, hyperfunction of corticotropin-releasing factor systems and their connections to the amygdala have been shown to mediate the negative emotional symptoms that occur during drug withdrawal.

Traditional experimental tests used to examine the sensitizing effects of drugs

There are three models used for testing behavioral and locomotor sensitization (Malanga and Kosofsky 2003). First, there are the Open Field and Laboras tests, which are conducted to test locomotor activity in an unknown environment induced by repeated drug administration, in anthropomorphic terms, a drug-induced euphoria (Malanga and Kosofsky 2003) (Fig. 1A). Then there are tests that measure conditioned drug-paired behavior: a) intravenous self-administration, in which an animal self-administers the drug, (Ferrario and Robinson 2007, Keller et al. 1996, Kučerová et al. 2009), and b) the Conditioned Place Preference test (the CPP test) (Fig. 1B), in which an animal demonstrates preference for an environment that has been associated with a drug (drug-seeking behavior based on conditioning; Malanga and Kosofsky 2003). It was discovered that the expression of behavioral sensitization is strengthened by the association of drug injection with environmental cues. Behavioral sensitization does not manifest when animals were tested in a context where drugs had never been experienced (Anagnostaras and Robinson 1996, Duvauchelle et al. 2000). Different types of animal behavior have previously been reported as a response to repeated psychostimulant administration (e.g. more intense stereotyped behavior including repetitive head movements, increased forward locomotion, rotational behavior, acoustic startle behavior, cage climbing, and others) (Malanga and Kosofsky 2003). There are few studies researching the behavioral expression of sensitization in humans, however, eye-blink responses, and increased vigor and energy ratings were shown to be caused by repeated administration of amphetamines in humans (Strakowski and Sax 1998). Moreover, drug re-administration has been shown to be followed by paranoia and psychosis (Pierce and Kalivas 1997, Robinson and Becker 1986).

Sensitization induced by prenatal drug exposure

Not only can sensitization be developed after repeated drug administration in adulthood, but drug exposure in utero can also cause changes in the developing brain of the fetus that lead to increased sensitivity to drugs administered in adulthood (Malanga and Kosofsky 2003). Exposure to drugs of abuse in utero can produce permanent changes in the central nervous system that are distinct from adaptations that occur in mature, homeostatically regulated animals (Stanwood and Levitt 2003).

MA is one of the most frequently abused drugs by female addicts, both in the Czech Republic and worldwide (Marwick 2000, Vavříková et al. 2001). Moreover, it is the favored drug of pregnant drug-abusing women, because it decreases appetite and food intake and therefore helps women to control their weight, while also increasing energy (Marwick 2000). Therefore, this drug has been of great interest when testing the sensitization developed after prenatal exposure.

Since MA is a lipophilic drug it can easily cross the blood-brain barrier (one of the most resistant barriers of the body), as well as the placental barrier, which is, comparatively, much more permeable (Greenhill 2006, Nordahl et al. 2003). In addition to other drugs, prenatal MA exposure has been shown to have harmful effects on...
both mothers and their offspring. Acuff-Smith et al. (1996) showed that repeated administration of MA to pregnant rats resulted in a higher incidence of delivery failure and maternal death. It also shortened the gestation period, decreased the number of pups per litter, and slowed weight gain during pregnancy (Martin 1975, Martin et al. 1976, Šlamberová et al. 2006). Moreover, prenatal MA exposure has been shown to affect development of postural movements in the pups during the first three weeks of postnatal life (Malinová-Ševčíková et al. 2014, Šlamberová et al. 2006, Šlamberová et al. 2007). There are also studies showing that changes in the brain caused by prenatal and neonatal MA exposure can persist into adulthood (Hrebíčková et al. 2014, Hrebíčková et al. 2016, Macúchová et al. 2016). Problems in adapting to new environments, long-term cognitive deficits, as well as changes in locomotor activity have also been previously linked to prenatal MA exposure (Schutová et al. 2013, Šlamberová et al. 2005, Weissman and Caldecott-Hazard 1993, Williams et al. 2003).

Various studies have found that prenatal exposure to psychostimulants results in enhanced responsiveness of mesostriatal monoaminergic projections (Rocha et al. 2002, Schneider et al. 2008, Vela et al. 1998). In a study by Bubeníková-Valešová et al. (2009), offspring with prenatal MA exposure had increased brain levels of DA after an acute dose of MA in adulthood, which suggests increased sensitivity to MA long after prenatal exposure. The effect of MA, administered prenatally, has been documented to be dose dependent. A low dose (2 mg/kg) of MA decreased the expression of DA transporters in the striatum and serotonin (5-HT) transporters in the hippocampus, striatum, and hypothalamus. On the other hand, a high dose (10 mg/kg) of MA increased the concentration of binding sites for the uptake of DA and 5-HT, suggesting that it stimulates growth of particular axon terminals (Weissman and Caldecott-Hazard 1993).

Methamphetamine at a dose of 5-20 mg/kg is used in experimental studies because it leads to drug concentrations in the brain that correspond to the amount in the fetuses of drug-dependent mothers (Acuff-Smith et al. 1996, Martin et al. 1976). However, there is still little known about how in utero MA exposure interacts with neurotransmitter systems of the developing brain or how this interaction affects the development of a predisposition for addiction in prenatally exposed offspring.

An increased tendency to abuse drugs in adulthood has been shown in prenatally MA-exposed (Schutová et al. 2010, Šlamberová et al. 2012, Šlamberová et al. 2011), COC-exposed (Keller et al. 1996, Rocha et al. 2002), cannabinoid-exposed (Vela et al. 1998), and morphine-exposed (Gigin et al. 1997) offspring compared to controls. For instance, in a study by Rocha et al. (2002), pregnant mice were given an injection with COC at two different doses. When their offspring reached adulthood, they were tested in self-administration experiments. The results showed that intrauterine exposure to COC contributed the sensitivity to COC self-administration. In another study by Vela et al. (1998), perinatal delta 9-tetrahydrocannabinol (THC) exposure affected susceptibility to the reinforcing effects of morphine in adulthood, which manifested as increased intravenous morphine self-administration in adult animals.

Šlamberová et al. (2005), introduced a drug injection paradigm for testing behavioral sensitization after prenatal drug exposure. Figure 2 describes a general pattern of induction of behavioral sensitization in prenatally drug exposed animals. When animals reach adulthood, they undergo various test situations with differing drug application (Macúchová et al. 2013, Schutová et al. 2009, Šlamberová et al. 2013, Šlamberová et al. 2012). Several abused drugs, which differ in their mechanism of action, can be used for testing behavioral sensitization. Methamphetamine is an indirect agonist at DA, noradrenaline (NA), and 5-HT receptors. Its main action is to increase the concentration of these three neurotransmitters through reverse transport, as well as uptake inhibition (Sulzer et al. 2005). The accepted opinion is that MA is more addictive and preferred by drug addicts than AMP and, despite structural similarities, MA has been suggested to be a more potent central stimulant with less peripheral activity (Peachey et al. 1977). On the other hand, in a study by Shoblock et al. 2003a and Shoblock et al. 2003b, AMP was shown to be more effective at rising DA levels in the prefrontal cortex than MA. Although, other authors have failed to find any differences in the potencies of AMP and MA in either inducing locomotor activity (Milesi-Halle et al. 2007) or inducing release of DA (Melega et al. 1995). Moreover, MA was shown to have three-fold greater potency than AMP in releasing 5-HT. This was first shown in 1960 by Whitty et al. (1960). They found that COC blocks re-uptake of catecholamine, which is now acknowledged to be the
primary means by which it increases extracellular levels of catecholamine. It has been demonstrated that COC binds with comparable affinity to NA, DA, and 5-HT receptors, while other studies have shown that the serotoninergic system is most affected by COC (Fleckenstein et al. 2000, Rothman and Baumann 2003). Similarly, N-methyl-3,4-methylenedioxymphetamine (MDMA) interacts with monoamine transporters to reverse the normal direction of transmitter flux and thus cause a non-exocytotic release of 5-HT, DA, and NA (Johnson et al. 1986, Spanos and Yamamoto 1989). MDMA exhibits a greater affinity for 5-HT- compared to DA transporters and recent in vitro experiments have suggested that MDMA is a stronger releaser of 5-HT than DA in the nervous system (Verrico et al. 2007). While morphine directly activates opioid receptors, and THC primarily interacts with cannabinoid receptors, both of these drugs indirectly increase DA and 5-HT release (Johnson and North 1992, Szabo et al. 2002).

This review summarizes the results of studies that focused on testing behavioral cross-sensitization after prenatal MA exposure. The drugs administered in adulthood were divided into two groups: a) MA and drugs that share the same mechanism of action as MA (amphetamine, cocaine, MDMA) (Milesi-Halle et al. 2007, Rothman and Baumann 2003, Spanos and Yamamoto 1989, Sulzer et al. 2005); and b) drugs with a different mechanism of action than MA (morphine and THC) (Johnson and North 1992, Szabo et al. 2002).

Fig. 2. A drug injection paradigm for testing behavioral sensitization after prenatal drug exposure. Animals are exposed to the prenatal drug during the entire gestation period (from day 1 to day 21). After reaching adulthood postnatal day (PD) 60-90, they experience various test situations with drug administration.

**Prenatally drug-induced cross-sensitization to drugs with similar mechanism of action**

The Laboras test revealed that in both male and female rats, prenatal MA exposure induced sensitization, but only to the psychostimulant effects of an acute dose of MA and AMP. Specifically, prenatally MA-exposed males and females compared to saline-exposed animals demonstrated increased locomotor and exploratory activity after acute MA and AMP treatment (Schutová et al. 2013, Šlamberová et al. 2013, Šlamberová et al. 2012). In contrast to results from the Laboras test, data from the CPP test failed to demonstrate any significant increase in active MA- and AMP-seeking behavior induced by prenatal MA exposure (Šlamberová et al. 2011). Based to these results, it has been suggested that although prenatal MA can sensitize animals to the psychostimulant effect of acute MA and AMP, it does not necessarily increase active drug-seeking behavior relative to these drugs. Only females, in the Laboras test, displayed sensitization induced by prenatal MA exposure to COC and MDMA (Šlamberová et al. 2013, Šlamberová et al. 2012). Specifically, prenatally MA-exposed females compared to saline-exposed females, demonstrated increased time spent in rearing movements after COC and MDMA treatment. The most likely explanation of this effect, which is found in females but not in males, might be based on sexual dimorphism relative to brain neurotransmitter system development. Vathy et al. (1993) and Vathy et al. (1995) showed that prenatal drug exposure affects the brain of females and males differently (particularly in terms of changes in neurotransmitter levels), suggesting that females might be more sensitive when exposed to other drugs in adulthood. These data regarding sex differences in sensitization are in agreement with studies by Melnick and Dow-Edwards (2001) and Peris et al. (1992), which suggested that sex differences correspond with
DA activity. More studies need to be conducted to see whether there are also sex differences in DA concentrations, after treatment with different drugs, which could support studies that found sex differences in sensitization.

Šlamberová et al. (2012) found avoidance rather than preference for the chamber associated with COC in animals with prenatal MA exposure, which indicates some kind of tolerance to COC treatment developed after MA exposure in utero. To the best of our knowledge, there are only two studies that also demonstrate tolerance to COC induced by prenatal MA exposure. Peltier et al. (1996) demonstrated that chronic treatment with psychostimulants, such as AMP and MA, produced cross-tolerance to both the discriminative and reinforcing effects of COC. In addition, it has been repeatedly shown that COC affects mostly the serotonergic system, while MA influences mainly the noradrenergic and dopaminergic systems (Fleckenstein et al. 2000, Rothman and Baumann 2003). This might explain why prenatal MA induces tolerance to the effects of COC (Gygi et al. 1996).

**Additional tests used for examining the sensitizing effect of drugs?**

Previous studies have shown that prenatal MA exposure might sensitize animals not only to the locomotor-stimulating effect of drugs administered later in adulthood, but could also be responsible for modified responses to various drug effects. For example, Schutová et al. (2010) found that prenatal MA altered the responsiveness of adult male rats to acute MA administration. Specifically, these results show that prenatally MA-exposed males demonstrated increased anxiolytic behavior in the Elevated Plus-Maze test compared to prenatally saline-exposed males. This indicates that prenatal MA exposure may increase the sensitivity of animals to the anxiogenic behavior induced by acute MA treatment. In the Social Interaction Test, although there were no interactions associated with locomotor activity (non-social behavior), an interesting result was found with regard to social behavior in groups of males treated in adulthood with MA, AMP, and MDMA. Specifically, prenatally MA-exposed males, when given an acute exposure to MA, AMP, and MDMA, showed decreased time spent in social interactions compared to saline-exposed animals treated in adulthood with the same drugs. It appears, that prenatal MA exposure sensitized the animals, resulting in reduced social behavior after receiving the same drugs as adults (Šlamberová et al. 2015).

Although, prenatal exposure to MA at a dose of 5 mg/kg does not lead to changes that persist until adulthood, in terms of worsened spatial learning, it does seem to cause some alterations, which in turn lead to different responses to the drug when administered in adulthood (Hrubá et al. 2010, Macúchová et al. 2013, Macúchová et al. 2014, Schutová et al. 2009). Alterations in swimming strategies, defined by using less spatial strategies of swimming and more scanning and thigmotaxis, can be seen after chronic treatment with MA, AMP (Macúchová et al. 2013, Macúchová et al. 2014, Schutová et al. 2009), as well as other drugs (COC, MDMA, THC, morphine (Macúchová et al. 2017).

**Conclusions**

To summarize, this review gives new insight into the problem of induced sensitization after prenatal MA exposure. Despite numerous studies investigating sensitization as a complex process arising from different
cellular changes in many regions of the brain, its neural basis is still not fully understood. MA is one of the more accessible drugs in the Czech Republic as well as worldwide, and in many cases, the first drug of choice for many drug-addicted pregnant women. Therefore, the question of whether children born to mothers, who abused MA during pregnancy, have an increased risk of substance abuse or other addictive behaviors after they grow up and enter adulthood is of critical importance. The question is particularly pertinent since events that stress neural development in prenatal life, can in many cases, lead to changes that persist until adulthood. This can consequently impair healthy development and future social inclusion of children as they mature. Since clinical studies are difficult to perform, developing a testable hypothesis through preclinical research can potentially increase the likelihood of finding a neurobiological basis for the increased predisposition for addiction in prenatally MA-exposed offspring. It has been shown that we cannot simply conclude that prenatal MA exposure leads to an increased sensitivity to abused drugs, and thus leads to the development of drug addiction.

The offspring of rats treated with MA during the entire gestational period can be sensitized to the application of other drugs in adulthood. Specifically, it seems that animals, after MA exposure in utero, demonstrate some kind of locomotor augmentation when exposed to psychostimulants (e.g. cocaine, amphetamine, or MDMA) later in adulthood. However, the increased locomotor reaction depends on the mechanism by which the drug acts. In addition, other test situations have revealed interactions between prenatal drug exposure and drug administration in adulthood. These are interesting findings that highlight the fact that the basis for sensitization may go beyond the classical concept of augmented locomotor reactions after drug treatment. Moreover, it seems that exposure to MA during the gestational period does not predispose offspring to an increased need for MA later in life. In anthropomorphic language, children of mothers who used MA during pregnancy might have an increased reaction to other drugs when they encounter them later in life, and this situation (i.e. the increased response) by itself might intensify their interest in using drugs.

**Conflict of Interest**

There is no conflict of interest.

**Acknowledgements**

This study was supported by research program Progres Q35 from Charles University. The authors express their appreciation to Thomas Ownsby Secrest, M.Sc. for critical reading and editing of the manuscript.

**Abbreviations**

5-HT – serotonin, AMP – amphetamine, AMPA – α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, COC – cocaine, CPP - the Conditioned Place Preference test, DA – dopamine, MA - methamphetamine, MDMA – N-methyl-3,4-methylenedioxyamphetamine, NA – noradrenaline, NAc – the nucleus accumbens, NMDA – N-methyl-D-aspartate receptor, PD – postnatal day, THC – delta9-tetrahydrocannabinol, VTA – the ventral tegmental area.

**References**


PU L, BAO GB, XU NJ, MA L, PEI G: Hippocampal long-term potentiation is reduced by chronic opiate treatment and can be restored by re-exposure to opiates. *J Neurosci* 22: 1914-1921, 2002.


